The argument arrives at a moment when the biology linking fat tissue to disordered breathing has never been clearer. Excess adiposity contributes to apnea through several well-characterized mechanisms. Fat deposited around the neck and tongue narrows and stiffens the pharyngeal airway, reducing the space available for airflow even before a patient falls asleep. Fat accumulated in the abdomen pushes upward on the diaphragm when a person lies down, lowering lung volumes and with them the traction that normally holds the upper airway open. Beyond these mechanical effects, adipose tissue is metabolically active, secreting inflammatory cytokines and hormones that appear to blunt the responsiveness of the muscles that keep the throat patent during sleep. The result is a disease in which the burden of fat, distributed across the body and within the airway itself, directly determines how often breathing stops each night.

The scale of the association is striking. An individual participant data meta-analysis of four community-based cohorts covering 12,860 adults, published in EClinicalMedicine in 2025, quantified the relationship between obesity and obstructive sleep apnea across large general populations rather than specialized clinics. Studies of this kind show that increases in body mass index are consistently accompanied by rises in the apnea-hypopnea index, the standard measure of how many times per hour a sleeper’s airflow is partially or completely obstructed. Yet the letter’s authors emphasize that such population-level correlations, however robust, still describe association. A heavy person may develop apnea because of fat, or because of a naturally narrow jaw, enlarged tonsils, or craniofacial anatomy inherited independently of weight. Without a framework for separating these contributors, clinicians cannot say how much of any individual patient’s disease is truly adiposity-driven.

Why does that distinction matter now? Because for the first time, therapies exist that can remove adiposity from the equation and measure what happens to the airway. The SURMOUNT-OSA trial, reported in the New England Journal of Medicine in 2024, tested tirzepatide, a dual incretin agonist already approved for obesity and type 2 diabetes, in patients with moderate to severe obstructive sleep apnea. The drug produced substantial weight loss and, crucially, large reductions in the apnea-hypopnea index, demonstrating that pharmacologically shrinking the body’s fat burden can directly unburden the sleeping airway. In the letter’s framing, such results transform the obesity-apnea relationship from a statistical observation into an experimentally testable causal claim, and they create a practical imperative to know in advance which patients stand to benefit most.

Surgical evidence points in the same direction. Bariatric surgery produces some of the largest and most durable weight reductions available in medicine, and studies of apnea outcomes after these procedures have repeatedly documented meaningful falls in the apnea-hypopnea index. But the improvements are rarely complete, and a substantial fraction of patients retain diagnosable sleep apnea even after losing large amounts of weight. That incomplete remission is itself informative. It suggests that while adiposity is a dominant and modifiable driver of the disease in many patients, non-adipose factors, from fixed airway anatomy to ventilatory control instability, persist independently. A formal definition of adiposity-attributable apnea would give clinicians a way to predict, before surgery or drug therapy, how much of a patient’s apnea is likely to resolve with weight loss and how much will require ongoing treatment with positive airway pressure or other modalities.

The mechanistic detail is advancing rapidly at the tissue level. Work published in the American Journal of Respiratory and Critical Care Medicine in 2020 examined what actually changes in the upper airway when patients lose weight, with particular attention to tongue fat. The researchers found that reductions in tongue volume tracked with improvements in the apnea-hypopnea index, underscoring that the location of fat loss matters as much as the total amount. The tongue is a muscular organ infiltrated by fat in obesity, and increased tongue fat both enlarges the structure and impairs the function of the muscles that keep it from falling back into the throat during sleep. This finding reframes weight loss for apnea not as a diffuse systemic effect but as a targeted anatomical intervention: shrink the tongue, open the airway. It also hints that future imaging could measure tongue fat directly, giving clinicians a biomarker for the adipose component of an individual’s disease.

Against this backdrop, the letter’s central proposal is conceptual rather than experimental. The authors, writing from five Indonesian institutions, argue that the field should formally define and characterize adiposity-attributable obstructive sleep apnea as a distinct clinical entity, much as medicine distinguishes, for example, secondary hypertension driven by a specific cause from essential hypertension of multifactorial origin. Such a definition would need operational criteria: measures of adiposity, ideally including regional depots like neck circumference and tongue fat; evidence that airway obstruction varies with those measures; and, ultimately, demonstration that interventions reducing fat reduce the apnea. The authors frame this as a shift from coexistence to causation, insisting that the discipline stop treating the two conditions as merely frequent bedfellows and start quantifying how much of the sleep apnea epidemic is, in a rigorous sense, a complication of obesity.

The implications ripple outward across clinical practice and public health. Obstructive sleep apnea affects an estimated hundreds of millions of adults worldwide, and its consequences extend far beyond snoring and daytime fatigue: untreated apnea is linked to hypertension, cardiovascular disease, stroke, type 2 diabetes, and impaired cognition. The standard treatment, continuous positive airway pressure, is effective but burdensome, and long-term adherence is notoriously poor. If a meaningful share of apnea is adiposity-attributable, then weight management, whether through lifestyle intervention, incretin-based pharmacotherapy, or metabolic surgery, becomes not an adjunct to apnea care but a potential disease-modifying therapy in its own right. Conversely, patients whose apnea is largely independent of weight would be spared unrealistic expectations that shedding kilograms will cure their disorder, allowing earlier and more appropriate escalation to airway-based treatments.

The letter also engages with a broader scientific conversation about sleep and obesity. A 2026 review in the same journal by Schmickl and colleagues, including sleep medicine researcher Atul Malhotra, mapped the known interactions between the two conditions and the open questions that remain, noting that the relationship is bidirectional. Sleep apnea fragments sleep and induces intermittent hypoxia, both of which dysregulate appetite hormones and promote weight gain, creating a vicious cycle in which each condition feeds the other. Disentangling cause and effect in such a loop is genuinely difficult, and the letter’s authors acknowledge that a definition of adiposity-attributable apnea will need to grapple with this bidirectionality: apnea may worsen the obesity that worsens the apnea. Careful longitudinal designs and mechanistic studies will be required to separate the forward and reverse arcs of the cycle.

What the proposal ultimately demands is a change in how the field measures success. If adiposity-attributable apnea becomes a recognized construct, trials of weight-loss therapies would be expected to report not just average apnea reductions but the proportion of patients whose disease remitted entirely, and studies would stratify participants by markers of the adipose contribution to their airway disease. Insurers and health systems, in turn, might one day cover weight-loss interventions for apnea on the same footing as airway pressure devices, justified by evidence that they address a root cause rather than a symptom. The letter, published on 24 August 2026 as volume 22, article 146 of the Journal of Clinical Sleep Medicine, is a call to sharpen a relationship that clinicians have taken for granted for decades. Its authors argue that the tools to do so, from incretin agonists and metabolic surgery to tongue-fat imaging and population-scale meta-analysis, already exist. What remains is the conceptual work of defining exactly when a disease of the sleeping airway is, at its core, a disease of fat.

Subject of Research: The causal role of adiposity in obstructive sleep apnea and the proposal to define adiposity-attributable sleep apnea as a distinct clinical entity

Article Title: From coexistence to causation: defining adiposity-attributable obstructive sleep apnea

Article References: Maizura, N., Andrianie, S., Bariyyah, K., Soejanto, L. T., Putri, S. N. J., & Ariyanto, R. D. (2026). From coexistence to causation: defining adiposity-attributable obstructive sleep apnea. Journal of Clinical Sleep Medicine, 22(1), Article 146. https://doi.org/10.1007/s44470-026-00175-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00175-8

Keywords: obstructive sleep apnea, obesity, adiposity, tirzepatide, bariatric surgery, tongue fat, apnea-hypopnea index, sleep medicine, weight loss, upper airway, causation, metabolic health